The kit is meant for use for the detection and quantitation of residual host cell protein.
Charles River Laboratories announced on Feb. 13, 2023 the launch of its first Enzyme-Linked Immunosorbent Assay (ELISA) kit for the detection and quantitation of residual host cell proteins (HCP) in Chinese hamster ovary (CHO)-based biotherapeutics.
The new HCP-ELISA kit leverages avian immunoglobulin Y (IgY) antibodies as the primary detection technology. These antibodies are derived from specific-pathogen-free chicken (SPF) eggs developed exclusively by AVS Bio. The HCP-ELISA kit builds upon Charles River’s HCP-GAPex service, increasing the efficiency and efficacy of HCP assay development.
“With more than 30 years of impurity testing experience, host cell protein assays are one of our core competencies,” said Kerstin Dolph, corporate senior vice president, biologics solutions, Charles River, in a company press release. “Building on that expertise to bring our inaugural kit to market was the next logical step to strengthen our Biologics Testing offering.”
Source: Charles River
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.